These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11695556)

  • 1. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative models for carcinogenicity testing.
    Cohen SM; Robinson D; MacDonald J
    Toxicol Sci; 2001 Nov; 64(1):14-9. PubMed ID: 11606797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
    van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
    Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53+/- hemizygous knockout mouse: overview of available data.
    Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
    Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xpa and Xpa/p53+/- knockout mice: overview of available data.
    van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
    Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expectations for transgenic rodent cancer bioassay models.
    Ashby J
    Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tg.AC genetically altered mouse: assay working group overview of available data.
    Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
    Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
    Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
    Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
    Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
    Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
    Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
    Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing.
    van Steeg H; Klein H; Beems RB; van Kreijl CF
    Toxicol Pathol; 1998; 26(6):742-9. PubMed ID: 9864090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
    Ward JM
    Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
    French J; Storer RD; Donehower LA
    Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors.
    Cohen SM
    Asian Pac J Cancer Prev; 2010; 11(1):15-7. PubMed ID: 20593920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.